Please Wait.....
Report
Fresenius Kabi AG - Strategic SWOT Insights - A 360 Review of Opportunities, Challenges and Risk, Corporate and ESG Strategies, Competitive Intelligence, and Recent Trends
Company Report I 2024-08-23 I 84 Pages I Quaintel Research
Report Summary
Fresenius Kabi AG - Strategic SWOT Insights - A 360 Review of Opportunities, Challenges and Risk, Corporate and ESG Strategies, Competitive Intelligence, and Recent Trends Report is a comprehensive and easily accessible overview of Fresenius Kabi AG's business operations. It provides a detailed analysis of the company's strategic standing, as well as its position in the industry compared to competitors. The report includes several key features to facilitate decision-making and provide insights into the company's performance.
The report begins with in-depth information about Fresenius Kabi AG including key insights, business segments, key executives, locations, products and services, historical events, corporate strategy, and management discussions. This section provides a solid foundation for understanding the company's key attributes.
Next, the report assesses Fresenius Kabi AG's strategic standing through various analyses. The ESG spotlight evaluates the company's environmental, social, and governance performance, providing insights into its sustainability efforts and ethical practices. The SWOT analysis examines the company's internal strengths and weaknesses, as well as external opportunities and threats. By integrating these strategic analyses, the report offers a comprehensive understanding of Fresenius Kabi AG's overall strategic standing and supports informed decision-making and strategic planning.
Finally, the report includes recent news and deal activities undertaken by Fresenius Kabi AG enhancing awareness of the company's business trends, growth perspectives, and more.
Key Highlights
Fresenius Kabi AG is a leading global healthcare company, specializes in lifesaving medicines and technologies for infusion, transfusion, and clinical nutrition. The company specializes in products for the therapy and care of critically and chronically ill patients. The portfolio includes biopharmaceuticals, clinical nutrition, MedTech products, intravenously administered generic drugs (generic IV drugs), and IV fluids. It have operations in over 100 countries and a workforce of approximately 40,000. With its Vision 2026, Fresenius Kabi has developed a strategic plan to transform the company for the next decade and to better capture new growth opportunities. Fresenius Kabi's corporate philosophy ''caring for life'' expresses the company's commitment to improving the quality of life of its patients. The quality and safety of its products and services is thus of paramount importance to Fresenius Kabi. The company have main research sites are in Europe, the United States, and India. The company have product-related development activities are also carried out in China.
Fresenius Kabi AG in the News:-
- 05-Aug-2024 - Fresenius Kabi Receives 2024 Trailblazer Award From Premier Inc. For Supply Chain Innovation
- 31-Jul-2024 - Fresenius With Excellent Performance in Q2; Major Progress on Deleveraging on the Back of Strong Cash Flow: Entering Target Ratio Corridor; Outlook Confirmed and Optimistic About Second Half
- 26-Jul-2024 - Fresenius Kabi and Formycon Receive Positive CHMP Opinion for FYB202, an Ustekinumab Biosimilar Candidate
- 11-Jul-2024 - Fresenius Announces EMA Validation of Marketing Authorization Application for Denosumab Biosimilar Candidates
- 05-Jul-2024 - Ideas for a Better Tomorrow
Scope
- Tactical Analysis:- Various strategic frameworks to gain insights into a company's competitive position and operational environment. These analytical tools assist in identifying competitive advantages, potential risks, and areas for improvement and efficiency, enabling companies to make informed tactical decisions.
- Business Strategy:- Contributes to shaping the company's overall direction, goals, and decision-making processes, ensuring long-term success and alignment with stakeholder expectations.
- Company Fundamentals:- These fundamentals offer valuable insights into the company's history, operations, leadership, and geographical presence, aiding in a comprehensive understanding of the organization.
- Competitive Landscape:- An identification of the company's main competitors, providing insights into the competitive landscape it operates in.
Reasons to Buy
- Comprehensive Understanding of the Fresenius Kabi AG's internal and external factors through SWOT analysis and Corporate Strategy.
- Strive Strategic Decision Making with various analyses and identifying potential customers and suppliers.
- Mitigate Risk with help of thorough analysis of internal and external factors. Furthermore, develop strategies and contingency plans to address these challenges and minimize their impact on business operations.
- Competitive Benchmarking will help to gain a competitive advantage by understanding industry trends, customer preferences, and best practices.
- Valuable insights from the report enable investors and partners to make informed decisions regarding potential Collaborations, Investments, or Partnerships with the company.
Additionally, available deep-dive analysis on the company Fresenius Kabi AG:
- Fresenius Kabi AG PESTLE Analysis
- Fresenius Kabi AG Value Chain Analysis
- Fresenius Kabi AG Porter's Five Forces Analysis
- Fresenius Kabi AG VRIO Analysis
- Fresenius Kabi AG BCG Analysis
- Fresenius Kabi AG Segmentation, Targeting and Positioning (STP) Analysis
- Fresenius Kabi AG Ansoff Matrix Analysis
Table of Contents
Table of Contents 2
Tables 6
Charts 7
Fresenius Kabi AG - Key Company Facts 8
Fresenius Kabi AG - Company Description 9
Fresenius Kabi AG - Top Executives 10
Fresenius Kabi AG - Top Executives Biographies 11
Fresenius Kabi AG - Head Office & Locations 13
Head Office - Country 13
Key Subsidiaries 14
Fresenius Kabi AG - Products and Services 16
Products 16
Fresenius Kabi AG - Historic Events 17
Fresenius Kabi AG - Company's Management Discussion 19
Fresenius Kabi AG - Company's Mission and Vision 22
Mission 22
Vision 22
Fresenius Kabi AG - Corporate Strategy 23
Fresenius Kabi AG - Business Description 29
Biopharma 30
Pharma 31
Medical Nutrition 32
MedTech 33
Fresenius Kabi AG - ESG Spotlight 35
Environment 35
Social 36
Corporate Governance 36
Fresenius Kabi AG - SWOT Analysis 37
Overview 37
Strengths 39
Weaknesses 42
Opportunities 44
Threats 47
Competing Players 49
Snapshot of Competing Players 50
Baxter International Inc. 50
Key Company Facts 50
Company Description 50
Becton, Dickinson and Company 52
Key Company Facts 52
Company Description 52
Roche Holding AG 54
Key Company Facts 54
Company Description 54
Johnson & Johnson 56
Key Company Facts 56
Company Description 56
Pfizer Inc. 58
Key Company Facts 58
Company Description 58
Fresenius Kabi AG - Business Signals 60
Signal Sentiments Analytics 60
Signal Segments Analytics 61
Signal Segments by Sentiments Analytics 62
Signals by Sentiments Analytics 65
Fresenius Kabi AG - In the News 69
05-Aug-2024 - Fresenius Kabi Receives 2024 Trailblazer Award From Premier Inc. For Supply Chain Innovation 69
31-Jul-2024 - Fresenius With Excellent Performance in Q2; Major Progress on Deleveraging on the Back of Strong Cash Flow: Entering Target Ratio Corridor; Outlook Confirmed and Optimistic About Second Half 71
26-Jul-2024 - Fresenius Kabi and Formycon Receive Positive CHMP Opinion for FYB202, an Ustekinumab Biosimilar Candidate 73
11-Jul-2024 - Fresenius Announces EMA Validation of Marketing Authorization Application for Denosumab Biosimilar Candidates 75
05-Jul-2024 - Ideas for a Better Tomorrow 75
30-Nov-2023 - Fresenius Kabi and Formycon Announce FDA Submission Acceptance for Review for Ustekinumab Biosimilar Candidate 76
01-Nov-2023 - Fresenius Kabi Launches Tyenne*, the First Approved Tocilizumab Biosimilar in the European Union 77
31-Oct-2023 - Supporting Conscious Choices in Nutritional Care 77
25-Oct-2023 - Gastrointestinal Dysfunction Study Wins Inaugural ESICM Clinical Nutrition Award 77
29-Sep-2023 - Fresenius Kabi and Formycon Announce EMA Submission Acceptance of the Marketing Authorization Application for FYB202, an Ustekinumab Biosimilar Candidate 77
19-Sep-2023 - Tyenne, Fresenius Kabi's Tocilizumab Biosimilar, Receives European Commission Approval 77
15-Sep-2023 - Fresenius Kabi Recognized as a Top Employer in 2023. Austria, China, Dominican Republic, Poland, Switzerland and the USA receive certificates 78
13-Sep-2023 - Jumpstart Clinical Nutrition Award Winner Announced at ESPEN Congress 78
17-Aug-2023 - Paving the Way for the Future of Blood Transfusions. Our novel blood bag system was subject of an award-winning clinical study 78
21-Jul-2023 - Fresenius Kabi's Tocilizumab Biosimilar Candidate MSB11456 Receives Positive CHMP Opinion 79
12-Jul-2023 - Fresenius Kabi's Denosumab Biosimilar Candidate FKS518 Shows Positive Clinical Trial Results 79
Fresenius Kabi AG - Key Deals 80
14-Dec-2023 - Fresenius Kabi and Mayo Clinic Enter into Multiyear Supply and Service Agreement for the Ivenix Infusion System 80
14-Sep-2023 - Virginia Oncology Associates Chooses the Ivenix Infusion System from Fresenius Kabi 80
24-Aug-2023 - Fresenius Kabi and Lupagen Enter Into Strategic Development and Supply Agreement to Bring Cell and Gene Therapies to the Bedside 80
07-Aug-2023 - Fresenius Kabi and Formycon Secure U.S. License Date for Proposed Ustekinumab Biosimilar 81
23-May-2023 - Fresenius Kabi Awarded Breakthrough Technology Agreement With Premier, Inc. For the Ivenix Infusion System 81
17-Apr-2023 - Vizient Innovative Technology Contract Awarded to Fresenius Kabi for the Ivenix Infusion System 81
02-Feb-2023 - Fresenius Kabi announces global license agreement with Formycon AG to commercialize proposed Ustekinumab biosimilar 81
10-Aug-2022 - Fresenius Kabi Establishes Partnership With Bio-Manguinhos/Fiocruz and Bionovis to Provide Access to Adalimumab Biosimilar in Brazil 81
01-Aug-2022 - Fresenius Kabi Completes Majority Stake Acquisition of mAbxience Holding S.L., Significantly Enhancing Presence in High-Growth Biopharmaceuticals Market 82
04-May-2022 - Fresenius Kabi completes acquisition of Ivenix, Inc., creating an industry-leading infusion therapies offering in the U.S. 82
Appendix 83
Definitions 83
SWOT Analysis 83
PESTLE Analysis 83
Value Chain Analysis 83
ESG Spotlight 83
Research Methodology 84
Disclaimer 85
Contact Us 85
Tables
Table 1: Fresenius Kabi AG - Company Facts
Table 2: Fresenius Kabi AG - Top Executives
Table 3: Fresenius Kabi AG - Top Executives Biographies
Table 4: Fresenius Kabi AG - Subsidiaries
Table 5: Fresenius Kabi AG - Products
Table 6: Fresenius Kabi AG - Historic Events
Table 7: Fresenius Kabi AG - Competing Players
Table 8: Competing Players - Baxter International Inc. - Key Company Facts
Table 9: Competing Players - Baxter International Inc. - Key Financials
Table 10: Competing Players - Becton, Dickinson and Company - Key Company Facts
Table 11: Competing Players - Becton, Dickinson and Company - Key Financials
Table 12: Competing Players - Roche Holding AG - Key Company Facts
Table 13: Competing Players - Roche Holding AG - Key Financials
Table 14: Competing Players - Johnson & Johnson - Key Company Facts
Table 15: Competing Players - Johnson & Johnson - Key Financials
Table 16: Competing Players - Pfizer Inc. - Key Company Facts
Table 17: Competing Players - Pfizer Inc. - Key Financials
Table 18: Fresenius Kabi AG - Business Signal Sentiments Analytics
Table 19: Fresenius Kabi AG - Business Signal Segments Analytics
Table 20: Fresenius Kabi AG - Business Signal Segments by Sentiments Analytics
Table 21: Fresenius Kabi AG - Business Signals by Sentiment Analytics
Table 22: Fresenius Kabi AG - Business Signal, Segment and Sentiment
Charts
Figure 1: Fresenius Kabi AG - SWOT Analysis
Figure 2: Competing Players - Baxter International Inc. - Key Financials
Figure 3: Competing Players - Becton, Dickinson and Company - Key Financials
Figure 4: Competing Players - Roche Holding AG - Key Financials
Figure 5: Competing Players - Johnson & Johnson - Key Financials
Figure 6: Competing Players - Pfizer Inc. - Key Financials
Figure 7: Fresenius Kabi AG - Business Signal Sentiments Analytics
Figure 8: Fresenius Kabi AG - Business Signal Segments Analytics
Figure 9: Fresenius Kabi AG - Business Signal Segments by Sentiments Analytics - Positive
Figure 10: Fresenius Kabi AG - Business Signal Segments by Sentiments Analytics - Negative
Figure 11: Fresenius Kabi AG - Business Signals by Sentiment Analytics - Positive
Figure 12: Fresenius Kabi AG - Business Signals by Sentiment Analytics - Negative
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security